Studio clinico NCT05086692 · Non-Small Cell Lung Cancer Squamous, Non-Small Cell Lung Cancer Non-squamous
NCT05086692 — risulta «attivo (non in reclutamento)» su ClinicalTrials.gov.
Studio clinico NCT05086692 (fase I/II) risulta «attivo (non in reclutamento)» su ClinicalTrials.gov.
Patologia: Non-Small Cell Lung Cancer Squamous, Non-Small Cell Lung Cancer Non-squamous · Interventi registrati: MDNA11, Pembrolizumab (KEYTRUDA®) · Date registrate (fonte): 2021-08-27, 2028-10-20, 2021-10-21, 2026-10-30.
Sintesi dello studio (fonte: ClinicalTrials.gov, testo originale in inglese):
This is a Phase 1/2, multi-center, open-label, dose-escalation and expansion study to evaluate safety and tolerability, PK, pharmacodynamic, and early signal of anti-tumor activity of MDNA11 alone or in combination with a checkpoint inhibitor in patients with advanced solid tumors.